ascendis transcon glp-1 program The Role of PEG in TransCon-Based Long-Acting Drug Development Novo Nordisk Taps Ascendis For
Description
Post hoc evaluations of the SUSTAIN 6 trial revealed that semaglutide markedly increased the incidence of diabetic retinopathy complications in individuals with a history of retinopathy, especially among insulin users, presumably due to the swift deterioration of pre-existing retinopathy following rapid glycemic control [91]
Most patients notice reduced appetite within the first one to two weeks as the medication reaches therapeutic levels
10,11,12 This prompts a renewed interest in examining the role of this peptide beyond the gastrointestinal tract
Telehealth simplifies follow-ups for patients on the mountain communities or across the river
